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Tetanus and botulinum neurotoxins type B and G are
zinc-endopeptidases of remarkable specificity. They
recognize and cleave a synaptic vesicle-associated mem-
brane protein (VAMP)/synaptobrevin, an essential pro-
tein component of the vesicle docking and fusion appa-
ratus. VAMP contains two copies of a nine-residuemotif,
also present in SNAP-25 (synaptosomal-associated pro-
tein of 25 kDa) and syntaxin, the two other substrates of
clostridial neurotoxins. This motif was suggested to be a
determinant of the target specificity of neurotoxins. An-
tibodies raised against this motif cross-react among
VAMP, SNAP-25, and syntaxin and inhibit the proteo-
lytic activity of the neurotoxins. Moreover, the various
neurotoxins cross-inhibit each other’s proteolytic ac-
tion. The role of the three negatively charged residues of
the motif in neurotoxin recognition was probed by site-
directed mutagenesis. Substitution of acidic residues in
both copies of the VAMPmotif indicate that the first one
is involved in tetanus neurotoxin recognition, whereas
the second one is implicated in binding botulinumB and
G neurotoxins. These results suggest that the two copies
of the motif have a tandem association in the VAMP
molecule.
Tetanus neurotoxin (TeNT)1 and botulinum neurotoxins
(BoNTs, seven types from A to G) are three-domain protein
toxins that bind selectively to the neuronal presynaptic mem-
brane. They are internalized inside intracellular compartments
from which the amino-terminal 50-kDa domain (termed L
chain) enters into the cytosol (1–4). The L chains of TeNT and
BoNTs are zinc-endopeptidases that cleave specifically three
proteins of the neuroexocytosis apparatus, thereby blocking
neurotransmitter release (4–7). TeNT and BoNT/B, BoNT/D,
BoNT/F, and BoNT/G recognize and cleave specifically a syn-
aptic vesicle-associated membrane protein (VAMP, also re-
ferred to as synaptobrevin) at different single peptide bonds (4,
8–12). BoNT/A and BoNT/E specifically recognize and cut
SNAP-25 (synaptosomal-associated protein of 25 kDa) at two
different peptide bonds near the COOH terminus (10, 13, 14),
whereas BoNT/C cleaves syntaxin (15, 16) and SNAP-25 (17–
19). VAMP, SNAP-25, and syntaxin are collectively termed
SNARE proteins, because they act as receptors of soluble N-
ethylmaleimide-sensitive factor accessory proteins, involved in
vesicle-membrane fusion (5–7).
Sequence comparison of the L chains of the eight clostridial
neurotoxins show strong similarities (20), which are even more
extensive at the level of predicted secondary structure (21).
These similarities suggest that they derive from a common
ancestral metalloproteinase. On this basis, to account for their
different substrate specificity, we considered the possibility
that the three SNAREs contain a common neurotoxin recogni-
tion site in addition to the cleavage sites specific for each
neurotoxin type. We identified a nine-residue-long motif
(SNAREmotif) present in eukaryotes only in the three proteins
known to be proteolytic substrates of the neurotoxins (22). The
SNARE motif is included within regions predicted to adopt an
a-helical conformation in the three SNAREs (23). This motif is
characterized by the presence of three negatively charged res-
idues and three hydrophobic residues spaced in such a way that
the Edmundson wheel plot shows a negatively charged surface
contiguous to a hydrophobic face. Preliminary experiments
showed that peptides corresponding to the motif sequence of
the three SNARES inhibit neurotoxin activity both in vitro and
in vivo in injected Aplysia neurons (22). We also suggested that
the specificity of the clostridial neurotoxin’s action is based on
a double recognition of their substrates via the SNARE motif
and via the segment containing the cleavage site (4, 22, 24).
Here we report on studies focusing on the interaction among
TeNT, BoNT/B and BoNT/G, and VAMP. Results obtained with
different experimental approaches provide strong evidence for
the involvement of the SNARE motif in this specific interac-
tion. Moreover, they show that negatively charged residues of
the motif play a major role in this interaction.
MATERIALS AND METHODS
Proteins, Peptides, and Chemicals—TeNT and BoNT/A, BoNT/B,
BoNT/C, BoNT/E, and BoNT/G were prepared as detailed before (25–
27). Immobilized metal ion affinity chromatography was used to remove
traces of contaminant proteases (28). Synaptosomes were isolated from
rat brain cortex as detailed before (10). Peptides V2 (ELDDRADALQ),
S3 (MLDEQGEQLER), and X2 (LEDMLESGN) were prepared with an
SMP 350 automatic synthesizer (Zynsser Analytic, Frankfurt), employ-
ing an Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry, and were
purified by reverse phase chromatography on a C8 Ultra-Sphere pre-
parative column (Beckman). The composition of soybean mixed lipids
(asolectin) was as described previously (29). Liposomes were obtained
by mixing chloroform/methanol (2:1) stock solutions of lipids. After
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drying under N2 flux, lipids were resuspended in diethyl ether, dried,
and sonicated until optical clarity was achieved.
Antibodies and Immunoblotting—Rabbit polyclonal antisera against
peptides V2, S3, and X2 were prepared as described by Kreis (30). The
antibodies were purified by affinity chromatography using activated
CH-Sepharose 4B (Pharmacia Biotech Inc.) conjugated with each pep-
tide. Antibody concentration was determined by the Bradford method
(31). Synaptosomes were transferred onto nitrocellulose as described
elsewhere (10) and treated with anti-V2, anti-S3, and anti-X2 antisera
(1:200). Primary antibodies were detected by immunostaining with an
anti-rabbit antibody (1:10,000 dilution, Boehringer Mannheim) conju-
gated with alkaline phosphatase (1:1,000; Sigma).
Bacterial Strains, Plasmid Construction, and VAMP Mutagenesis—
The VAMP-2 gene was generated by inserting a PCR-derived DNA
fragment from the rat VAMP-2 cDNA clone characterized previously
(32). This DNA fragment covers the complete sequence of the VAMP-2
gene and has BamHI and EcoRI restriction sites at the 59 and 39 ends,
respectively. It was inserted into the pEMBL8- plasmid (33). Uracil
containing single-stranded DNA was produced within BW313, an Esch-
erichia coli dut- ung- strain, for generation of VAMP-2 mutants by
site-directed mutagenesis. The in vitro reactions were performed as
described by Kunkel et al. (34). The following oligonucleotides were
used to generate the corresponding mutants: 59-TGCGCGATTAT-
TCAGTTCC-39 for VAMP-2 D64N,D65N; 59-GGAGGGCATTTGCGC-
GAT-39 for VAMP-2 D68N; the combination of the two previous oligo-
nucleotides for VAMP-2 D64N,D65N,D68N; 59-CTGCGCGACTAC-
TCAGTTCC-39 for VAMP-2 D64S,D65S, and 59-TCCACCACCTGAT-
TCACCTGG-39 for VAMP-2 D40N,E41Q. The sequence of the mutated
genes was checked by dideoxy sequencing using the fmole DNA se-
quencing System (Promega). Wild type VAMP-2 and mutants were
subcloned into BamHI and EcoRI sites of pGEX-KG vector (35) and
transformed into the AB1899 strain of E. coli.
VAMP Protein Expression and Purification—Rat VAMP-2 and rat
VAMP-2 mutants were expressed as GST fusion proteins and were
purified by affinity chromatography on GSH-agarose matrix (Pharma-
cia) as before (12).
Assay of Proteolytic Activity—GST-fusion VAMPs (50 mg/ml final
concentration) were incubated with a sonicated clear liposome suspen-
sion (final concentration, 1 mg of soya bean mixed phospholipids/ml) at
37 °C for 1 h. After treatment with dithiothreitol (10 mM for 30 min at
37 °C), TeNT (200 nM), BoNT/B, or BoNT/G (40 nM) was added to the
reaction mixture, containing one of the different GST fusion proteins.
Proteolysis was carried out in 150 mM NaCl, 10 mM Na2HPO4, pH 7.4,
at 37 °C for variable periods of time. In some experiments 1 mg of
GST-VAMP-2 was preincubated for 30 min with affinity-purified anti-
bodies (1 mM), specific for the different peptides, before neurotoxin
addition and proteolysis, as described above. Samples were analyzed in
a 15% polyacrylamide SDS gels and, after silver staining of proteins,
scanned with a dual wavelength Shimadzu CS-630 densitometer.
For neurotoxin competition experiments, GST-VAMP-2 was preincu-
bated for 1 h at 37 °C with each one of the three neurotoxins, BoNT/A,
BoNT/E, and BoNT/C, which do not cleave VAMP-2 (1 mM) in 150 mM
NaCl, 10 mM Na2HPO4, 0.3 mM CaCl2, 2 mM MgCl2, pH 7.4. Proteolytic
cleavage was carried out for 2 h at 37 °C with TeNT 200 nM or BoNT/B
40 nM. All neurotoxins were preincubated with dithiothreitol 10 mM in
the same cleavage buffer for 30 min at 37 °C.
RESULTS
Anti-SNARE Motif Antibodies Specifically Recognize VAMP,
SNAP-25, and Syntaxin—Available models for neuroexocytosis
assign a central role to VAMP, SNAP-25, and syntaxin, the
three targets of clostridial neurotoxins (5–7). These proteins
form an SDS-resistant heterotrimeric complex able to bind
SNAPs and N-ethylmaleimide-sensitive factor (23, 36, 37). Fig.
1 depicts the three SNAREs and includes membrane-spanning
segments and sites of cleavage of clostridial neurotoxins. There
are two copies of the motif in VAMP (V1 and V2), four copies in
SNAP-25 (S1, S2, S3, and S4), and two copies in syntaxin (X1
and X2). Little structural information is available for isolated
SNARE proteins. If the motif is to serve as neurotoxin recog-
nition site, it has to be exposed at the protein surface, where it
may act as an epitope and bind antipeptide specific antibodies.
To test this possibility, rabbits were immunized with keyhole
limpet hemocyanin coupled with the V2, S3, or X2 peptide, and
IgGs were purified after booster immunization with the same
antigens. Fig. 2 shows that the rabbit IgGs specific for V2 do
recognize VAMP, but they also stain syntaxin and SNAP-25,
FIG. 1. Schematic structure of VAMP, SNAP-25, and syntaxin with cleavage sites of neurotoxins and positions of SNAREmotif (a).
The SNARE motif is composed of nine residues and contains three conserved carboxylate residues (2) at positions 2, 3, and 6; in an Edmundson
wheel plot of the motif Glu or Asp residues clusters on one-third of the helix. This motif is present in two copies in VAMP-2 (V1 and V2), two copies
in syntaxin (X1 and X2), and four in SNAP-25 (S1, S2, S3, and S4). Capital letters correspond to the proteolytic cleavage site of tetanus toxin (T)
and of the seven botulinum neurotoxins from A to G. Dark dots identify the transmembrane region of VAMP and syntaxin. The lower part of the
figure reports the sequences of the various copies of the SNARE motif (b).
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although with lower intensity. In parallel, anti-S3 rabbit IgGs
show binding to syntaxin and to VAMP in addition to the
expected recognition of SNAP-25, and a similar pattern of
staining is observed with X2-specific antibodies. The immuno-
genicity of the SNARE motif, at the basis of the SNARE cross-
reactivity, is also supported by the fact that rabbit polyclonal
antisera prepared against recombinant VAMP or SNAP-25 or
syntaxin stain all three SNARE proteins (Fig. 2). This result
puts a word of caution on the interpretation of immunofluores-
cence studies performed with antibodies raised against an en-
tire SNARE protein.
Anti-SNARE Motif Antibodies Interfere with VAMP Proteol-
ysis by Tetanus and Botulinum Neurotoxins—The involvement
of the SNARE motif in neurotoxin binding leads to the predic-
tion that antimotif-specific antibodies should inhibit the pro-
teolytic activity of neurotoxins. Fig. 3a shows that antibodies
prepared against V2, S3, or X2 have an inhibitory effect on
TeNT and BoNT/B proteolysis of VAMP. The extent of protec-
tion is variable and incomplete. This may be accounted for by
variable affinities of the different antibodies and by the fact
that the antibody competes with the neurotoxin for only one of
the two sites of interaction between VAMP and the neurotoxin.
SNAP-25 and Syntaxin-specific Neurotoxins Inhibit Tetanus
and Botulinum Neurotoxin Proteolysis of VAMP—Another pre-
diction of the model, outlined in the Introduction, is that each
clostridial neurotoxin should be able to bind any SNARE pro-
tein, although only one of them (two in the case of BoNT/C)
would be cleaved, depending on the fitting of a particular
sequence into each neurotoxin active site (4). As a consequence,
binding of any neurotoxin type to a SNARE should inhibit its
proteolysis by the specific neurotoxin. Fig. 3b shows the results
of neurotoxin cross-inhibition experiments performed with
FIG. 2. Antibody cross-reactions among VAMP, SNAP-25, and
syntaxin. Rat brain synaptosomes were electrophoresed and blotted
onto nitrocellulose membranes. Samples were incubated with rabbit
anti-SNARE motif-specific polyclonal antibodies anti-V2, anti-S3, and
anti-X2 affinity-purified as detailed under “Materials and Methods.”
The last three samples were incubated with rabbit anti-VAMP-2, anti-
SNAP-25, or antisyntaxin antisera and were stained with the appro-
priate alkaline phosphatase-conjugated anti-IgG antibodies.
FIG. 3. Inhibition of VAMP cleavage
by tetanus and botulinum B neuro-
toxins with anti-SNARE motif-spe-
cific antibodies and non-VAMP-spe-
cific neurotoxins. a, the amount of
cleavage of GST-VAMP2 fusion protein
incubated with tetanus neurotoxin
(TeNT) or botulinum neurotoxin B
(BoNT/B) alone or in the presence of af-
finity-purified antibodies against pep-
tides V2, S3, and X2 after 2 h at 37 °C. b,
GST-VAMP-2 was preincubated with
BoNT/A, BoNT/E, or BoNT/C, previously
reduced with dithiothreitol, and then re-
duced TeNT and BoNT/B were added and
incubated for 2 h at 37 °C. Data are the
average of three independent experi-
ments, and bars represent S.D. values.
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VAMP as a substrate: TeNT and BoNT/B proteolysis of VAMP
is inhibited by BoNT/A, BoNT/C, and BoNT/E. The inhibitory
effect is not complete and differs for BoNT/A, BoNT/C, and
BoNT/E. This is to be attributed to the fact that BoNT/A,
BoNT/C, and BoNT/E bind VAMP via a single interaction with
the SNARE motif, whereas TeNT and BoNT/B interact with
VAMP at two sites: the SNARE motif and the segment around
the cleavage site. The result of Fig. 3b indicates that BoNT/A
interacts with the SNARE motif more strongly than BoNT/C
and BoNT/E. Similar inhibitory effects were found when TeNT
or BoNT/B were present in assays of proteolysis of SNAP-25 by
BoNT/A and BoNT/E (not shown).
Mutation of the Negatively Charged Residues of V2 Affects
VAMP Cleavage by Botulinum B and G—As shown in Fig. 1,
the SNARE motif is characterized by the presence of three
negatively charged residues, which cluster on a face if the motif
is arranged in an a-helix. As a first approach to the study of the
role of the different residues of the motif in neurotoxin speci-
ficity, each of the three aspartic residues of the V2 segment of
VAMP was replaced with asparagine. This mutation was cho-
sen because it is the most conservative substitution compatible
with the removal of the negative charge of the carboxylate
residue. Such mutant VAMPs were purified as GST fusion
proteins from E. coli extracts, and the proteolytic activity of
VAMP-specific clostridial neurotoxins was tested. Previous
studies with VAMP segments of different lengths (11, 23,
38–40) implicated V2 in BoNT/B and BoNT/G binding of
VAMP (4, 24).
Fig. 4 shows that progressive replacement of the three Asp
residues of the V2 segment of VAMP with Asn residues causes
a progressive loss of proteolytic activity of BoNT/B and
BoNT/G. The effect of the D68N replacement appears to be
larger for BoNT/G than for BoNT/B, although the lower enzy-
mic activity of BoNT/G may be partially responsible for this
effect. On the contrary, TeNT cleaves the three VAMP mutants
at similar rates. On the basis of the close structural similarity
between clostridial neurotoxins, this result was unexpected.
However, it is possible that TeNT binds V2 via hydrogen bond-
ing interactions, which can be formed both with Asp and with
Asn lateral chains. Therefore, the two Asp residues 64 and 65
of V2 were converted into Ser residues, which are hydrophilic
but have a much smaller lateral chain. The VAMP-2 D64S,
D65S mutant is, however, cleaved by TeNT at a rate very
similar to that of wild type VAMP-2 (Fig. 5).
Mutation of the Negatively Charged Residues of V1 Affects
VAMP Cleavage by Tetanus Neurotoxin, but Not by Botulinum
B and GNeurotoxins—Another possibility that may account for
the results of Fig. 5a is that TeNT recognizes VAMP via an
interaction with V1, rather than V2. To test this possibility,
Asp40 and Glu41 of VAMP-2 were replaced by the corresponding
Asn and Gln residues. Fig. 6 shows that this VAMP-2 mutant
is not cleaved by TeNT (panel a), while the same protein is
proteolyzed by BoNT/B as efficiently as the wild type VAMP-2
(panel b). These results indicate that TeNT and BoNT/B, the
only two clostridial neurotoxins that recognize and cleave the
same target protein at the same peptide bond (8), actually
differ from each other. They are identical with respect to the
consequence of their proteolysis because the same two VAMP
fragments are generated. But they differ in their mode of sub-
strate recognition, because this recognition is mediated by two
different segments of VAMP.
VAMPs mutated in V1 and V2 were also tested as proteolytic
substrates of TeNT and BoNT/B in the presence of BoNT/A.
The ability of this latter toxin to inhibit TeNT and BoNT/B
FIG. 4. Neurotoxin proteolysis of VAMPs containing mutations that progressively remove the negative charges of the V2 SNARE
motif. The rate of proteolysis of GST-VAMP-2 and the GST-VAMP-2 mutants are indicated (top right) with TeNT (panel a), BoNT/B (panel b), and
BoNT/G (panel c), determined as detailed under “Materials and Methods.” Samples were removed at 5, 30, and 120 min, electrophoresed, and
silver-stained, and the amount of protein was determined by densitometric scanning. Data are the average of four different experiments, and bars
represent S.D. values.
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proteolysis of VAMP, documented in Fig. 3b, was reduced when
VAMP-2 D64S,D65S mutant and the VAMP-2 Asp40 and Glu41
were assayed (not shown). However, results did not allow us to
draw a clear conclusion of a possible preference of BoNT/A
between V1 and V2.
DISCUSSION
The light chain of the eight clostridial neurotoxins have a
unique specificity for VAMP, SNAP-25, and syntaxin, termed
SNAREs (5–7). Their three-dimensional structure is not
known. Available spectroscopic and biochemical data, as well
as comparison of their primary and predicted secondary struc-
ture, indicate that they are closely similar. Nonetheless, they
show unique proteolytic activity exerted on different peptide
bonds of three different protein substrates. Short peptides en-
compassing the cleavage site of VAMP-2 cannot be cleaved by
TeNT and BoNT/B. For proteolysis to occur, long VAMP pep-
tides, including V2 and/or V1, are required (4, 38–41). Hence,
the neurotoxin’s specificity cannot be explained by the sole
recognition of the cleavage site (4, 39). A negatively charged
motif was identified in the three SNAREs, and it was suggested
that it is implicated in their selective recognition by clostridial
neurotoxins (22, 24). Here, we report strong evidence in favor of
the involvement of the SNAREmotif in the interaction between
VAMP and TeNT and BoNT/B and BoNT/G. 1) Antibodies,
raised against motif peptides or recombinant proteins, recog-
nize and cross-react among the three SNAREs, despite subtle
sequence differences in the specific SNARE motifs of VAMP,
SNAP-25, and syntaxin. This result indicates that this is a
FIG. 5. Tetanus and botulinum B neurotoxin proteolysis of VAMP mutants containing Asp 3 Ser substitutions in the V2 motif.
GST-VAMP-2 and mutants with Ser residues replacing Asp residues at positions 64 and 65 (D64S.D65S) were incubated with TeNT (panel a) or
BoNT/B (panel b) as described in the legend to Fig. 4. Data are the average of three independent experiments, and bars are S.D. values.
FIG. 6. Substitution of the carboxylate residues in positions 40 and 41 of VAMP abolishes proteolysis with tetanus neurotoxin but
not with botulinum B neurotoxin. GST-VAMP-2 and GST-VAMP-2 mutants in which two carboxylated residues of the V1 motif were replaced
with the corresponding amide groups (D40N.E41Q) were incubated with TeNT (panel a) or BoNT/B (panel b) under the same conditions of Fig. 4.
Samples were removed at 5, 30, 60, and 120 min, electrophoresed, silver-stained, and quantitated by densitometric scanning. Data are averages
of three independent experiments, and bars are S.D. values.
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common structural element of SNAREs. 2) Occupation of the
motif with an antibody or with a non-VAMP-specific neurotoxin
inhibits VAMP proteolysis by TeNT and BoNT/B. The partial
and variable inhibitory effects observed can be explained by the
fact that antibodies and neurotoxins can compete for only one
of the two sites involved in the specific binding of the appro-
priate neurotoxin type. 3) Mutation of the acidic residues of the
motif leads to resistance of VAMP to the neurotoxin proteoly-
sis. Based on the clostridial neurotoxin similarity mentioned
above, we had assumed that TeNT and BoNT/B, which cleave
VAMP at the same peptide bond, were also similar in their
recognition. Hence, we were expecting that mutation in V2, the
SNARE motif copy next to the cleavage site, would affect to a
similar extent TeNT and BoNT/B proteolysis of VAMP. The
results of the mutagenesis experiments reported here clearly
show that TeNT, BoNT/B, and BoNT/G are all different from
each other, not only from the serological point of view, but also
with respect to their interaction with VAMP. The two botuli-
num neurotoxins interact with the same V2 segment but cleave
VAMP at two different peptide bonds (8, 12). Conversely, TeNT
and BoNT/B cleave VAMP at the same peptide bond (8) but
recognize VAMP via two additional different segments: V1 and
V2, respectively. This result explains the recent finding of
Foran et al. (40) that BoNT/B, but not TeNT, cleaves a peptide
corresponding to the VAMP-2-(55–94) segment and that TeNT
requires an amino-terminal extension of 12 residues to cleave
efficiently. The present results are potentially relevant also
with respect to VAMP structure. All available data suggest
that the L chains of TeNT and BoNT/B fold very similarly. If
this is the case, a corresponding structural similarity must be
present in the VAMP structure. In other words, the present
results are best explained by assuming that V1 and V2 occupy
spatially equivalent positions with respect to the Gln76–Phe77
peptide bond cleaved by TeNT and BoNT/B. We suggest that
V1 and V2 are arranged as a tandem association in the VAMP
structure and that this particular three-dimensional organiza-
tion plays a role in the biological function of VAMP. Recently,
Kelly and colleagues (42, 43) have analyzed exoendocytosis in
cells transfected with VAMP mutants deleted in various por-
tions of the molecule. It was found that deletion of V1 leads to
a deficient targeting of VAMP-2 to the synaptic vesicles. Hence,
it appears that tetanus neurotoxin interacts with a crucial part
of the VAMP molecule, a part that cannot be altered without
negative consequences for a fundamental physiological process.
Our findings are very relevant to the possible engineering of
TeNT- or BoNT-cleavable domain in a protein whose function is
to be abolished at any given time in a cell by toxin exposure.
This is suggested by a recent study in which tetanus toxin light
chain was expressed in Drosophila and it was found that only
one of the two VAMP isoforms was cleaved by TeNT. The two
Drosophila VAMPs have an identical sequence at the cleavage
site, but in the TeNT-resistant VAMP isoform a Gly residues
replaces the third Asp residue within the V1 motif (44).
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